Autoimmune dementia: clinical course and predictors of immunotherapy response.

OBJECTIVE To define the diagnostic characteristics and predictors of treatment response in patients with suspected autoimmune dementia. PATIENTS AND METHODS Between January 1, 2002, and January 1, 2009, 72 consecutive patients received immunotherapy for suspected autoimmune dementia. Their baseline clinical, radiologic, and serologic characteristics were reviewed and compared between patients who were responsive to immunotherapy and those who were not. Patients were classified as responders if the treating physician had reported improvement after immunotherapy (documented in 80% by the Kokmen Short Test of Mental Status, neuropsychological testing, or both). RESULTS Initial immunotherapeutic regimens included methylprednisolone in 56 patients (78%), prednisone in 12 patients (17%), dexamethasone in 2 patients (3%), intravenous immune globulin in 1 patient (1%), and plasma exchange in 1 patient (1%). Forty-six patients (64%) improved, most in the first week of treatment. Thirty-five percent of these immunotherapy responders were initially diagnosed as having a neurodegenerative or prion disorder. Pretreatment and posttreatment neuropsychological score comparisons revealed improvement in almost all cognitive domains, most notably learning and memory. Radiologic or electroencephalographic improvements were reported in 22 (56%) of 39 patients. Immunotherapy responsiveness was predicted by a subacute onset (P<.001), fluctuating course (P<.001), tremor (P=.007), shorter delay to treatment (P=.005), seropositivity for a cation channel complex autoantibody (P=.01; neuronal voltage-gated potassium channel more than calcium channel or neuronal acetylcholine receptor), and elevated cerebrospinal fluid protein (>100 mg/dL) or pleocytosis (P=.02). Of 26 immunotherapy-responsive patients followed up for more than 1 year, 20 (77%) relapsed after discontinuing immunotherapy. CONCLUSION Identification of clinical and serologic clues to an autoimmune dementia allows early initiation of immunotherapy, and maintenance if needed, thus favoring an optimal outcome.

[1]  V. Lennon,et al.  IMMUNOTHERAPY-RESPONSIVE DEMENTIAS AND ENCEPHALOPATHIES , 2010, Continuum.

[2]  D. Friedman,et al.  Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen , 2010, The Lancet Neurology.

[3]  D. Lachance,et al.  Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. , 2009, Archives of neurology.

[4]  R. Kalb,et al.  AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location , 2009, Annals of neurology.

[5]  A. Vincent,et al.  CLINICAL SPECTRUM OF VOLTAGE-GATED POTASSIUM CHANNEL AUTOIMMUNITY , 2009, Neurology.

[6]  Xiaoyu Peng,et al.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies , 2008, The Lancet Neurology.

[7]  B. Boeve,et al.  Young-onset dementia: demographic and etiologic characteristics of 235 patients. , 2008, Archives of neurology.

[8]  M. Geschwind,et al.  Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. , 2008, Archives of neurology.

[9]  E. Benarroch,et al.  Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  J. Parisi,et al.  Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases. , 2008, Journal of neurosurgery.

[11]  J. Stack,et al.  Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. , 2007, Archives of neurology.

[12]  K. Josephs,et al.  Whole-body tremulousness: isolated generalized polymyoclonus. , 2007, Archives of neurology.

[13]  V. Lennon,et al.  Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. , 2006, Gastroenterology.

[14]  E. Benarroch,et al.  Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. , 2006, Mayo Clinic proceedings.

[15]  B. Boeve,et al.  Steroid-responsive encephalopathy associated with autoimmune thyroiditis. , 2006, Archives of neurology.

[16]  V. Lennon,et al.  Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome , 2004, Annals of neurology.

[17]  O. Barsottini,et al.  Progressive encephalomyelitis with rigidity: a paraneoplastic presentation of oat cell carcinoma of the lung. Case report. , 2004, Arquivos de neuro-psiquiatria.

[18]  M. Rossor,et al.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. , 2004, Brain : a journal of neurology.

[19]  A. Godbolt,et al.  The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia , 2004, Journal of Neurology.

[20]  Ronald C Petersen,et al.  Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. , 2003, Archives of neurology.

[21]  E. Benarroch,et al.  CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity , 2001, Annals of neurology.

[22]  E. Kaplan,et al.  The Boston naming test , 2001 .

[23]  G. Farrugia,et al.  Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. , 2000, The New England journal of medicine.

[24]  B. Scheithauer,et al.  Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy. , 1999, Neurology.

[25]  R. Mandler,et al.  Morvan's Fibrillary Chorea: Electrodiagnostic and In Vitro Microelectrode Findings , 1998, Annals of the New York Academy of Sciences.

[26]  E. Tangalos,et al.  Mayo's older Americans normative studies: category fluency norms. , 1998, Journal of clinical and experimental neuropsychology.

[27]  C. Lucchinetti,et al.  Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies , 1998, Neurology.

[28]  N. Squires,et al.  Construct validity in the Trail Making Test: what makes Part B harder? , 1995, Journal of clinical and experimental neuropsychology.

[29]  J. French,et al.  The incidence of thyroid disorders in the community: a twenty‐year follow‐up of the Whickham Survey , 1995, Clinical endocrinology.

[30]  E. Tangalos,et al.  The short test of mental status. Correlations with standardized psychometric testing. , 1991, Archives of neurology.

[31]  T. Walls,et al.  Hashirnoto's encephalopathy , 1991, Neurology.

[32]  W. Castelli,et al.  The aging thyroid. Thyroid deficiency in the Framingham Study. , 1985, Archives of internal medicine.

[33]  H. Gharib,et al.  Correlation of thyroid antibodies and cytologic features in suspected autoimmune thyroid disease. , 1983, The American journal of medicine.

[34]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[35]  L. Brain,et al.  Hashimoto's disease and encephalopathy. , 1966, Lancet.

[36]  P. Rubé,et al.  L’examen Clinique en Psychologie , 1959 .

[37]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[38]  T. Q. Irigaray,et al.  Intellectual abilities in Alzheimer's disease patients: Contributions from the Wechsler Abbreviated Scale of Intelligence (WASI) , 2010 .

[39]  David Wechsler,et al.  Wechsler Memory scale. , 2005 .

[40]  Gary J. Robertson,et al.  Wide Range Achievement Test 3 ( wrat3 ) , 2001 .

[41]  E. Tangalos,et al.  Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO , 1996 .

[42]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .

[43]  R. Reitan.  Trail Making Test: Manual for Administration and Scoring , 1992 .

[44]  P. Shaw,et al.  Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers--report of 5 cases. , 1991, Neurology.